Neogen Chemicals Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/vykutnqczh21rolkwgd9t47w.pdf

Key Takeaways


Lithium Strategy & Battery Materials

Dr. Harin Kanani: "In terms of lithium salts, international customers, who are making electrolyte or who are making other electrolytes, the requirement is today because it is being consumed even today. ... Whereas, for electrolyte, the Indian customers are still taking time to start consuming the electrolytes."

Margin & Cost Structure

Dr. Harin Kanani: "I am very happy to say that our team worked really well with the right procurement at the right time; getting into back-to-back contracts, where we ensured that in spite of a historical 4-5 times increase in lithium prices, still we were able to pass on all the lithium prices to our customers while basically protecting our absolute EBITDA margin."

Demand Environment

Dr. Harin Kanani: "Sometimes we have seen prices from China, which is really difficult to believe, are historically low. Sometimes, we even believe that this is a very good case for anti-dumping, because they are basically selling at a very, very low price, which even raw material does not make sense."

Customer & Product Mix Shift


Capacity & CapEx


Guidance & Commitments

CommitmentSpecificsTimeline
FY23 revenue₹650-700 cr (up from earlier ₹600 cr target, depending on lithium)FY23
FY23 EBITDA₹100-110 crFY23
FY24 revenue₹700-725 crFY24
Lithium salt derivatives plant commissioning400 MT plant ready; trial production beginsCommissioning by Q4 FY23; trials by Q1 FY24
Electrolyte plant readinessPlant readyQ1 or Q2 FY24
Organic chemical capacity completionAdditional capacity onlineQ1 or maximum Q2 FY24
CSM revenue share20% of ~₹750 cr revenueFY24
FY25/FY26 additional revenue at full utilisation₹250-300 cr from lithium capacity, reactor volumes, and battery material saltsFY25/FY26
Advanced intermediates revenue potential~₹150 cr from six molecules, contributing from H2Peak by FY25
Tax rate improvementAt least 25-26% or belowBy year-end FY23
Pharma demand normalisationReturn to normal demand levelsSix months to one year from Q2 FY23
Working capital improvementInventory levels lower than September 2022By March 2023
Working capital days target~110-120 days of stock inventory on net salesFY24
Lithium-ion battery materials CapEx decisionBased on final customer confirmationsAnytime between now and March 2023
Debt-equity ratioAround 1:1, max 1.25 for short period, otherwise below 1:1Ongoing

Key Metrics

MetricQ2 FY23
Revenue₹148.1 cr, +31% YoY
Organic chemicals revenue₹99 cr, +9% YoY
Inorganic chemicals revenue₹49 cr, +122% YoY (from ₹22 cr in Q2 FY22)
Domestic:Export mix50:50
EBITDA₹24.3 cr, +18% YoY
PAT₹9.9 cr
H1 FY23 revenue₹296 cr, +50% YoY
H1 FY23 EBITDA₹48.9 cr, +35% YoY
H1 FY23 PAT₹21 cr, +13% YoY
FY23 full-year revenue guidance₹650-700 cr, depending on lithium price behaviour in H2
FY23 full-year EBITDA target₹100-110 cr
FY24 revenue guidance₹700-725 cr
Additional revenue by FY25/FY26 at full utilisation₹250-300 cr
Mahape and Karakhadi utilisation80-85%
Dahej site utilisation60-65%
CSM revenue share15% in H1 FY23, target 20% by FY24
R&D team size60 members
H1 FY23 operating cash flownegative ₹93 cr
Net debt~₹250 cr
Employee cost as a percentage of revenue~8%, historically highest level
H1 FY23 effective tax rate~29%
New customers added in the quarter5, across Europe and Japan, combined revenue potential of more than ₹200 cr
Advanced intermediates revenue potential~₹150 cr, pilots and/or first commercial run completed
Lithium salt derivatives plant peak revenue potential~₹100 cr at full utilisation
Small electrolyte trial capacity200 kg per month